Nektar Therapeutics (NKTR) Stock Price Down 5.2%

Nektar Therapeutics (NASDAQ:NKTR) shares dropped 5.2% during trading on Wednesday . The stock traded as low as $32.17 and last traded at $32.61. Approximately 2,221,576 shares changed hands during mid-day trading, an increase of 19% from the average daily volume of 1,860,162 shares. The stock had previously closed at $34.41.

NKTR has been the topic of several research reports. Mizuho reissued a “buy” rating on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Goldman Sachs Group began coverage on Nektar Therapeutics in a research note on Thursday, December 13th. They set a “buy” rating and a $62.00 target price for the company. BidaskClub upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th. Piper Jaffray Companies set a $100.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, ValuEngine downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 31st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and a consensus price target of $73.92.

The company has a debt-to-equity ratio of 0.14, a current ratio of 17.53 and a quick ratio of 17.39. The company has a market cap of $6.08 billion, a price-to-earnings ratio of 8.63 and a beta of 3.09.



Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13. Nektar Therapeutics had a return on equity of 50.22% and a net margin of 57.09%. During the same period in the prior year, the business earned ($0.21) earnings per share. On average, research analysts forecast that Nektar Therapeutics will post -3.01 EPS for the current fiscal year.

In related news, COO John Nicholson sold 63,000 shares of Nektar Therapeutics stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $42.82, for a total value of $2,697,660.00. Following the completion of the transaction, the chief operating officer now directly owns 237,477 shares in the company, valued at $10,168,765.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Howard W. Robin sold 108,882 shares of Nektar Therapeutics stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $42.19, for a total value of $4,593,731.58. Following the completion of the transaction, the chief executive officer now owns 350,924 shares of the company’s stock, valued at $14,805,483.56. The disclosure for this sale can be found here. Insiders sold 241,824 shares of company stock valued at $10,249,993 over the last quarter. Insiders own 4.31% of the company’s stock.

A number of large investors have recently bought and sold shares of NKTR. Wells Fargo & Company MN grew its stake in shares of Nektar Therapeutics by 129.7% during the 3rd quarter. Wells Fargo & Company MN now owns 414,142 shares of the biopharmaceutical company’s stock valued at $25,246,000 after acquiring an additional 233,819 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in shares of Nektar Therapeutics by 148.2% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 11,876 shares of the biopharmaceutical company’s stock valued at $724,000 after acquiring an additional 7,092 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of Nektar Therapeutics by 21.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,320 shares of the biopharmaceutical company’s stock valued at $994,000 after acquiring an additional 2,863 shares during the period. ING Groep NV bought a new position in shares of Nektar Therapeutics during the 3rd quarter valued at approximately $313,000. Finally, SG Americas Securities LLC grew its stake in shares of Nektar Therapeutics by 6.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,465 shares of the biopharmaceutical company’s stock valued at $2,833,000 after acquiring an additional 2,881 shares during the period. Institutional investors and hedge funds own 93.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Stock Price Down 5.2%” was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/03/21/nektar-therapeutics-nktr-stock-price-down-5-2.html.

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: Call Option

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.